The Q1 2023 quarterly report can be accessed using the link below

Dedicated to the treatment of metabolic, fibrotic and inflammatory diseases using our drug discovery platform and data-driven approach

Browse our resources hub for the latest news and information

About us

Liminal BioSciences is a development-stage biopharmaceutical company focused on developing distinctive novel small molecule therapeutics for metabolic, fibrotic and inflammatory diseases using our drug discovery platform and data-driven approach.

Product pipeline

Our expertise in small molecules has enabled a strong pipeline with potential first/best-in-class drug candidates.

Investors

Find out more on how Liminal BioSciences (NASDAQ: LMNL) is developing a pipeline of novel small molecule therapeutics.